Verrica Pharmaceuticals Inc.: capital expenditure payments
Capital expenditure payments for Verrica Pharmaceuticals Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Verrica Pharmaceuticals Inc. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2018-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 0 | USD | 2026-03-11 | 10-K · 0001660334-26-000008 |
| 2024-01-01 | 2024-12-31 | 27,000 | USD | 2026-03-11 | 10-K · 0001660334-26-000008 |
| 2023-01-01 | 2023-12-31 | 362,000 | USD | 2025-03-11 | 10-K · 0000950170-25-037172 |
| 2022-01-01 | 2022-12-31 | 302,000 | USD | 2024-02-29 | 10-K · 0000950170-24-022659 |
| 2021-01-01 | 2021-12-31 | 883,000 | USD | 2023-03-06 | 10-K · 0000950170-23-006118 |
| 2020-01-01 | 2020-12-31 | 1,470,000 | USD | 2022-03-02 | 10-K · 0000950170-22-002685 |
| 2019-01-01 | 2019-12-31 | 682,000 | USD | 2021-03-17 | 10-K · 0001564590-21-013876 |
| 2018-01-01 | 2018-12-31 | 774,000 | USD | 2020-03-13 | 10-K · 0001564590-20-010832 |
Related financial histories
- Verrica Pharmaceuticals Inc.: total assets
- Verrica Pharmaceuticals Inc.: total liabilities
- Verrica Pharmaceuticals Inc.: stockholders equity
- Verrica Pharmaceuticals Inc.: cash and cash equivalents
- Verrica Pharmaceuticals Inc.: net income or loss
- Verrica Pharmaceuticals Inc.: operating cash flow
- Verrica Pharmaceuticals Inc.: contract revenue excluding tax
- Verrica Pharmaceuticals Inc.: financing cash flow
- Verrica Pharmaceuticals Inc.: investing cash flow
- Verrica Pharmaceuticals Inc.: retained earnings or deficit
- Verrica Pharmaceuticals Inc.: basic weighted-average shares
- Verrica Pharmaceuticals Inc.: diluted weighted-average shares
- Verrica Pharmaceuticals Inc.: basic earnings per share
- Verrica Pharmaceuticals Inc.: diluted earnings per share
- Verrica Pharmaceuticals Inc.: net property, plant and equipment
- Verrica Pharmaceuticals Inc.: operating income or loss
- Verrica Pharmaceuticals Inc.: current assets
- Verrica Pharmaceuticals Inc.: interest expense
- Verrica Pharmaceuticals Inc.: current liabilities
- Verrica Pharmaceuticals Inc.: current accounts payable
- Verrica Pharmaceuticals Inc.: net current accounts receivable
- Verrica Pharmaceuticals Inc.: operating expenses
- Verrica Pharmaceuticals Inc.: net inventory
- Verrica Pharmaceuticals Inc.: selling, general and administrative expense
- Verrica Pharmaceuticals Inc.: research and development expense
Inspect the source
- Entity
- Verrica Pharmaceuticals Inc. / CIK 0001660334
- Captured
- 2026-09-21T17:23:55.666Z
- SEC response SHA-256
6beecb7e5e9ec42164512d13952b7c46a3974532ad5360a386c3a54cd53ea9d0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001660334.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))